Evidence map›Paper›PMID 40964112›Full record

ReviewSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025

[The Role of Fasting-Mimicking Diet in Cancer Therapy: Mechanisms, Challenges, and Clinical Prospects].

Yuanxin Liu, Laiyan Zhou, Jianxin Xue

Abstract readReviewEnglish Abstract
In one paragraph

Review in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yuanxin Liu( 610041) Division of Thoracic Tumor Multimodality Treatment, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.ORCID 0009-0004-2319-0545
Laiyan Zhou( 610041) Division of Thoracic Tumor Multimodality Treatment, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Jianxin Xue( 610041) Division of Thoracic Tumor Multimodality Treatment, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.ORCID 0000-0003-4501-7538

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The fasting-mimicking diet (FMD), an emerging cyclic low-calorie dietary intervention strategy, has garnered significant attention in the field of tumor therapy with its ability to remodelthe body's metabolic and immune microenvironment. Studies have shown that FMD not only extends the lifespan and reduces the incidence of cancer and other diseases in healthy individuals, but also enhances the protective effects on normal cells. Furthermore, FMD increases the sensitivity of tumor cells to multiple therapeutic treatments. FMD activates the protective pathways of normal cells by lowering the levels of blood glucose, insulin, and insulin-like growth factor-1, while it induces differential stress sensitization of tumor cells, thereby enhancing the sensitivity of cancer cells to tumor therapy and providing new targets for individualized therapy. Herein, we provide a brief overview of the fundamental concept of FMD, the underlying mechanisms, and its potential application in cancer treatment, highlighting the synergistic effects of FMD applied in combination with conventional cancer therapies, such as chemotherapy and immunotherapy. Moreover, the challenges encountered in translating FMD into clinical practice are discussed, along with the promising future applications of this dietary regimen.

Indexed as

Caloric RestrictionDietFastingNeoplasmsAnimalsBlood GlucoseHumansImmunotherapyInsulin-Like Growth Factor IBlood GlucoseInsulin-Like Growth Factor ICancer therapyFasting-mimicking dietNutritionReview

Identifiers

PMID40964112
PMCPMC12439641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.